KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Receivables (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Change in Receivables for 4 consecutive years, with -$5.8 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Receivables rose 90.24% year-over-year to -$5.8 million, compared with a TTM value of -$55.7 million through Sep 2023, down 185.78%, and an annual FY2025 reading of $1.5 million, down 68.83% over the prior year.
  • Change in Receivables was -$5.8 million for Q3 2023 at Ginkgo Bioworks Holdings, up from -$17.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $85.4 million in Q4 2021 and bottomed at -$59.1 million in Q3 2022.
  • Average Change in Receivables over 4 years is $4.3 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw Change in Receivables skyrocketed 519.82% in 2021, then plummeted 568.58% in 2023.
  • Year by year, Change in Receivables stood at $13.8 million in 2020, then surged by 519.82% to $85.4 million in 2021, then plummeted by 140.39% to -$34.5 million in 2022, then soared by 83.27% to -$5.8 million in 2023.
  • Business Quant data shows Change in Receivables for DNA at -$5.8 million in Q3 2023, -$17.2 million in Q2 2023, and $1.8 million in Q1 2023.